The University of Maryland Biotechnology Institute has spun off a new company. Omic Biosystems, based in Rockville, will study proteins to identify drug discoveries and disease treatments in order to develop technologies that will solve significant problems in the field of proteomics.
The newly formed company will attempt to commercialize a technology called DiART (deuterium (2H) isobaric amine reactive tags) that uses protein tagging designs coupled with sample preparation technology for use in large-scale modern mass spectrometry proteomics studies.
The immediate market impact of this technology is its utility in biomarker discoveries," says Jonathan Gottlieb, director of Technology Transfer and Commercialization at UMBI. "Its broader impact will facilitate the translation of genomic and proteomic information into relevant clinical information that can be applied to new drug discovery and clinical diagnostics."
Source: Jonathan Gottlieb, UMBI
Writer: Walaika Haskins